Injectable Blood Thinners

Overview of Injectable Anticoagulants

• The American College of Chest Physicians recommends the use of injectable anticoagulants, including unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), fondaparinux, direct thrombin inhibitors, and danaparoid, for the prevention and treatment of thromboembolic disorders 1, 2

Low-Molecular-Weight Heparins (LMWHs)

• The American College of Chest Physicians suggests that LMWHs, such as enoxaparin, dalteparin, and tinzaparin, have largely replaced UFH for many indications due to their superior pharmacokinetic properties 1, 3
• The FDA has approved enoxaparin for both VTE prophylaxis and immediate treatment, as well as acute coronary syndromes 4, 5
• Dalteparin is approved for VTE prophylaxis and extended treatment of symptomatic VTE in cancer patients 4, 5
• Tinzaparin is currently approved only for immediate VTE treatment 4, 5
• Nadroparin is used in Europe and Canada for VTE prophylaxis and treatment 3, 7

Unfractionated Heparin (UFH)

• The American College of Chest Physicians recommends the use of UFH, administered intravenously or subcutaneously, for therapeutic anticoagulation, requiring monitoring with activated partial thromboplastin time (APTT) 1, 2

Synthetic Pentasaccharide

• Fondaparinux, a synthetic pentasaccharide, selectively inhibits Factor Xa through antithrombin-dependent mechanisms, and is administered once daily subcutaneously in fixed doses without coagulation monitoring 1, 2

Direct Thrombin Inhibitors

• The American College of Chest Physicians suggests the use of direct thrombin inhibitors, such as hirudin, bivalirudin, and argatroban, as alternatives to heparin in patients with HIT 1, 2

Key Advantages of LMWHs Over Unfractionated Heparin

• LMWHs have a predictable dose-response, approximately 90% bioavailability after subcutaneous injection, eliminating the need for routine monitoring 1, 3
• LMWHs have a longer half-life, 3-6 hours, allowing once or twice daily dosing 1, 3
• LMWHs have a lower bleeding risk, reduced major bleeding compared to UFH for equivalent antithrombotic effect 7
• LMWHs have a reduced HIT risk, decreased binding to platelets and platelet factor 4 1, 3
• LMWHs have a lower osteoporosis risk, reduced binding to osteoblasts 1, 3